SLXP - This is a tough condition to run a trial in, and I think the clinicians on the panel will be sympathetic to that. Remember this is just a label expansion (albeit with a higher dose I think) - this is an approved drug. Here's some discussion of existing treatments: http://content.nejm.org/cgi/content/full/337/7/473 Peter